Header Logo

Connection

Patrick Arbuthnot to Mice

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Mice.
Patrick Arbuthnot
Connection Strength
1,796
Mice
  1. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,172
  2. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
    View in: PubMed
    Score: 0,162
  3. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,127
  4. Hepatic Delivery of Artificial Micro RNAs Using Helper-Dependent Adenoviral Vectors. Methods Mol Biol. 2016; 1364:249-60.
    View in: PubMed
    Score: 0,125
  5. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,112
  6. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,106
  7. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem. 2013 Oct 15; 21(20):6145-55.
    View in: PubMed
    Score: 0,104
  8. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun. 2010 Aug 06; 398(4):640-6.
    View in: PubMed
    Score: 0,086
  9. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.
    View in: PubMed
    Score: 0,076
  10. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,074
  11. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat. 2007 Jul; 14(7):447-59.
    View in: PubMed
    Score: 0,070
  12. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007 Mar; 15(3):534-41.
    View in: PubMed
    Score: 0,067
  13. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,062
  14. Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector. Virol J. 2025 Feb 17; 22(1):41.
    View in: PubMed
    Score: 0,059
  15. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,047
  16. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,046
  17. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
    View in: PubMed
    Score: 0,041
  18. Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice. Sci Rep. 2017 02 03; 7:41874.
    View in: PubMed
    Score: 0,034
  19. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996 Aug 20; 7(13):1503-14.
    View in: PubMed
    Score: 0,033
  20. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology. 1995 Dec; 22(6):1788-96.
    View in: PubMed
    Score: 0,031
  21. In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Sci Rep. 2015 Jul 03; 5:11842.
    View in: PubMed
    Score: 0,030
  22. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
    View in: PubMed
    Score: 0,025
  23. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010 Apr 19; 143(2):222-32.
    View in: PubMed
    Score: 0,021
  24. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009 May-Jun; 6(3):706-17.
    View in: PubMed
    Score: 0,020
  25. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
    View in: PubMed
    Score: 0,017
  26. Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004 May; 40(1):34-46.
    View in: PubMed
    Score: 0,014
  27. Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 2002 Jul-Aug; 4(4):355-68.
    View in: PubMed
    Score: 0,012
  28. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology. 2001 Jul; 34(1):146-57.
    View in: PubMed
    Score: 0,011
  29. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene. 1999 Mar 04; 18(9):1677-87.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.